The U.S. Court of Appeals for the Federal Circuit on Dec. 1 upheld an administrative board’s decision that two vaccine technology patents owned by a subsidiary of Canadian drugmaker Arbutus Biopharma were valid.
The decision means Arbutus could sue Moderna and request royalties for its COVID-19 vaccine, which uses a similar vaccine delivery technology as the one covered under the patents.
A Moderna spokesperson told Becker’s it disagrees with the court’s decision and does not believe its vaccine falls under Arbutus’ patents.
“Moderna is a pioneer of mRNA-based vaccines, and we have developed our own proprietary [lipid nanoparticle]-delivery technology,” the spokesperson said.
Moderna is also facing a separate dispute with the National Institutes of Health regarding whether federal scientists should have been listed as co-inventors of Moderna’s COVID-19 shot in a patent application.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
